In the latest trading session,, 0.55 million Amicus Therapeutics Inc (NASDAQ:FOLD) shares changed hands as the company’s beta touched 0.65. With the company’s most recent per share price at $7.39 changing hands around $0.04 or 0.61% at last look, the market valuation stands at $2.27B. FOLD’s current price is a discount, trading about -71.18% off its 52-week high of $12.65. The share price had its 52-week low at $6.20, which suggests the last value was 16.1% up since then. When we look at Amicus Therapeutics Inc’s average trading volume, we note the 10-day average is 3.69 million shares, with the 3-month average coming to 2.96 million.
Analysts gave the Amicus Therapeutics Inc (FOLD) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.50. If we narrow down to specifics, the data shows that 1 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended FOLD as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Amicus Therapeutics Inc’s EPS for the current quarter is expected to be 0.08.
Amicus Therapeutics Inc (NASDAQ:FOLD) trade information
Instantly FOLD is in green as seen in intraday trades today. With action 10.21%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -21.50%, with the 5-day performance at 10.21% in the green. However, in the 30-day time frame, Amicus Therapeutics Inc (NASDAQ:FOLD) is -13.91% down. Looking at the short shares, we see there were 17.98 million shares sold at short interest cover period of 5.0 days.
The consensus price target for the stock as assigned by Wall Street analysts is 14.5, meaning bulls need an upside of 49.03% from its recent market value. According to analyst projections, FOLD’s forecast low is 13 with 19 as the target high. To hit the forecast high, the stock’s price needs a -157.1% plunge from its current level, while the stock would need to soar -75.91% for it to hit the projected low.
Amicus Therapeutics Inc (FOLD) estimates and forecasts
Year-over-year growth is forecast to reach 19.48% up from the last financial year.
Consensus estimates given by 10 financial analysts project the company’s revenue in the current quarter to hit an average of 136.35M. 10 analysts are of the opinion that Amicus Therapeutics Inc’s revenue for the current quarter will be 150.39M. The company’s revenue for the corresponding quarters a year ago was 110.4M and 126.67M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 23.50%. The estimates for the next quarter sales put growth at 18.73%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 34.10%. The 2025 estimates are for Amicus Therapeutics Inc earnings to increase by 114.06%.
FOLD Dividends
Amicus Therapeutics Inc is expected to release its next quarterly earnings report on 2025-Feb-18.
Amicus Therapeutics Inc (NASDAQ:FOLD)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.69% of Amicus Therapeutics Inc shares while 100.41% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 101.11%. There are 100.41% institutions holding the Amicus Therapeutics Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 9.4111% of the shares, roughly 28.59 million FOLD shares worth $283.6 million.
PERCEPTIVE ADVISORS LLC holds the second largest percentage of outstanding shares, with 9.2363% or 28.06 million shares worth $278.33 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jan 31, 2025 were VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 20.89 shares estimated at $153.88 million under it, the former controlled 6.80% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 3.03% of the shares, roughly 9.3 shares worth around $68.48 million.
